ERBB2 and colorectal carcinoma: While an impressively high degree of concordance (97.9%) has been described between cfDNA and tissue ERBB2 amplification status of CRC patients enrolled in the HERACLES trial (27), a head-to-head comparison of tissue and blood-based test results in larger patient cohorts will be necessary to define and develop HER2 positivity criteria.